Literature DB >> 1618703

Kinetic analysis of combination effect of navelbine (KW-2307) with cisplatin against human lung adenocarcinoma PC-12 cells in culture.

K Gomi1, H Ohno, K Nomura, M Okabe, K Kobayashi, H Niitani.   

Abstract

The combination effect of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, and cisplatin (CDDP) was compared with that of vindesine (VDS) and CDDP using human lung adenocarcinoma PC-12 cells. The growth-inhibitory activity of NVB or VDS was time-dependent, whereas that of CDDP was AUC (area under the curve)-dependent. When NVB or VDS was used in combination with CDDP simultaneously for 24 h, antagonism was observed in terms of growth-inhibitory activity. However, additive combination effect was observed when NVB or VDS treatment was followed by CDDP treatment. On this treatment schedule, a synergistic combination effect was observed in terms of the cell-killing activity assessed by colony formation assay. The growth-inhibitory activity of NVB or VDS was detected 24 h after the treatment, whereas that of CDDP became significant 72 h after the treatment. NVB and VDS caused cell accumulation in G2M phase at 10 times their IC80 values, and cells with less than diploid DNA content were detected after 24 h at IC80. CDDP caused accumulation of cells in S phase, and the effect became detectable 16 h after the treatment. The DNA histogram of cells treated with NVB or VDS in combination with CDDP was a superposition of those of cells treated with each drug alone. Significant differences in the characteristics of anticellular activity were not detected between NVB and VDS, although NVB inhibited cell growth at a slightly lower concentration than VDS at the short exposure time of 1-8 h.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1618703      PMCID: PMC5918847          DOI: 10.1111/j.1349-7006.1992.tb01961.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


area under the curve cisplatin combination index navelbine Dulbecco's phosphate‐buffered saline vincristine vindesine vinblastinel concentration required for 50% growth inhibition concentration required for 80% growth inhibition.
  26 in total

1.  Phase-II study of Navelbine in advanced breast cancer.

Authors:  L Canobbio; F Boccardo; G Pastorino; F Brema; C Martini; M Resasco; L Santi
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

2.  Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells.

Authors:  S Ozawa; Y Sugiyama; J Mitsuhashi; M Inaba
Journal:  Cancer Res       Date:  1989-07-15       Impact factor: 12.701

3.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

Authors:  T C Chou; P Talalay
Journal:  Adv Enzyme Regul       Date:  1984

4.  Experimental antitumor activity of 5'-nor-anhydrovinblastine navelbine.

Authors:  R Maral; C Bourut; E Chenu; G Mathé
Journal:  Cancer Lett       Date:  1984-02       Impact factor: 8.679

5.  Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells.

Authors:  G Del Bino; J S Skierski; Z Darzynkiewicz
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

6.  In vitro cytokinetic response of human colon cancer cells to cis-dichlorodiammineplatinum(II).

Authors:  J P Bergerat; B Barlogie; W Göhde; D A Johnston; B Drewinko
Journal:  Cancer Res       Date:  1979-11       Impact factor: 12.701

7.  A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.

Authors:  J C Ruckdeschel; D M Finkelstein; D S Ettinger; R H Creech; B A Mason; R A Joss; S Vogl
Journal:  J Clin Oncol       Date:  1986-01       Impact factor: 44.544

8.  Vindesine in the treatment of esophageal carcinoma: a phase II study.

Authors:  D P Kelsen; M Bains; E Cvitkovic; R Golbey
Journal:  Cancer Treat Rep       Date:  1979 Nov-Dec

9.  Characteristics of antiviral and anticellular activities of human recombinant interferon-gamma.

Authors:  K Gomi; M Morimoto; N Nakamizo
Journal:  Jpn J Cancer Res       Date:  1985-03

10.  Kinetic analysis of 5-fluorouracil action against various cancer cells.

Authors:  M Inaba; J Mitsuhashi; S Ozawa
Journal:  Jpn J Cancer Res       Date:  1990-10
View more
  3 in total

Review 1.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 2.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

3.  Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro.

Authors:  K Sugiyama; M Shimizu; T Akiyama; H Ishida; M Okabe; T Tamaoki; S Akinaga
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.